List of Protein Therapies Companies in Switzerland - 2

Search through the full list with powerful filtering options

Company	About
Nerai Bio Zurich, Switzerland	Nerai Bio is a biotech startup pioneering ultra-specific genome editing technologies to treat genetic diseases. Using their AI-driven MORPHEME platform, they engineer novel gene-editing proteins that can precisely target and correct DNA at any location, addressing a broader range of genetic mutations than existing tools like CRISPR. Their lead therapeutic candidates focus on severe liver disorders, aiming to provide a single, permanent cure for conditions currently treated with lifelong care. Recently, Nerai Bio secured CHF 150,000 from Venture Kick to advance business development, preclinical validation studies, and partnerships.
Relief Therapeutics Geneva, Switzerland	Relief Therapeutics Holding AG, a biopharmaceutical company, provides patients with therapeutic relief from serious diseases with high unmet medical need in Switzerland, rest of Europe, North America, and internationally. The company focuses on clinical-stage programs based on molecules with a history of clinical use and either initial human activity or efficacy data or a strong scientific rationale. Its lead compound is RLF-100 (aviptadil), a synthetic human vasoactive intestinal peptide (VIP) with a multifaceted mode of action for respiratory indications, which is in Phase 3 clinical trials for treating COVID-19-induced acute respiratory distress syndrome and moderate to severe COVID-19 lung injury; in Phase 1 clinical trial for the treatment of patients with acute lung injury in other intensive care unit; and in Phase 2 clinical trial for the treatment of pulmonary sarcoidosis. The company is also developing ACER-001, a proprietary powder formulation of sodium phenylbutyrate, which has completed Phase 3 clinical trial for urea cycle disorders; and in Phase 1 clinical trial for the treatment of maple syrup urine disease. In addition, it is developing APR-TD011, a spray-formulated hypotonic acid-oxidizing solution, which is in Phase 2 clinical trial for treating epidermolysis bullosa. The company was founded in 2013 and is based in Geneva, Switzerland.

Company

About

Nerai Bio

Zurich, Switzerland

Nerai Bio is a biotech startup pioneering ultra-specific genome editing technologies to treat genetic diseases. Using their AI-driven MORPHEME platform, they engineer novel gene-editing proteins that can precisely target and correct DNA at any location, addressing a broader range of genetic mutations than existing tools like CRISPR. Their lead therapeutic candidates focus on severe liver disorders, aiming to provide a single, permanent cure for conditions currently treated with lifelong care. Recently, Nerai Bio secured CHF 150,000 from Venture Kick to advance business development, preclinical validation studies, and partnerships.

Relief Therapeutics

Geneva, Switzerland

Relief Therapeutics Holding AG, a biopharmaceutical company, provides patients with therapeutic relief from serious diseases with high unmet medical need in Switzerland, rest of Europe, North America, and internationally. The company focuses on clinical-stage programs based on molecules with a history of clinical use and either initial human activity or efficacy data or a strong scientific rationale. Its lead compound is RLF-100 (aviptadil), a synthetic human vasoactive intestinal peptide (VIP) with a multifaceted mode of action for respiratory indications, which is in Phase 3 clinical trials for treating COVID-19-induced acute respiratory distress syndrome and moderate to severe COVID-19 lung injury; in Phase 1 clinical trial for the treatment of patients with acute lung injury in other intensive care unit; and in Phase 2 clinical trial for the treatment of pulmonary sarcoidosis. The company is also developing ACER-001, a proprietary powder formulation of sodium phenylbutyrate, which has completed Phase 3 clinical trial for urea cycle disorders; and in Phase 1 clinical trial for the treatment of maple syrup urine disease. In addition, it is developing APR-TD011, a spray-formulated hypotonic acid-oxidizing solution, which is in Phase 2 clinical trial for treating epidermolysis bullosa. The company was founded in 2013 and is based in Geneva, Switzerland.